MAPT and Alzheimer disease: 18F-MK-6240 is a validated neuroimaging biomarker for the detection of tau pathology in AD, aiding in distinguishing AD from non-AD four-repeat tauopathies such as progressive supranuclear palsy and corticobasal degeneration [[2], [3]].